



Customer No.: 27160

PATENT  
DOCKET NO.: 114205.1200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 28 2001

In reapplication of:  
DENISE R. COOPER AND NIKETA A. PATEL )  
Serial No.: 09/435,471 )  
Filed: November 8, 1999 )  
)

Group Art Unit: 1643 TECH CENTER 1600/2900  
Examiner: Anne-Marie Baker, Ph.D.

Title: INTRODUCTION OF A GLUCOSE-REGULATED INSTABILITY ELEMENT VIA  
ALTERNATIVE EXON INCLUSION OF PKCBII mRNA IN VASCULAR SMOOTH  
MUSCLE CELLS

Commissioner for Patents  
Washington, D.C. 20231

STATEMENT IN SUPPORT OF SEQUENCE RULE SUBMISSIONS

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821 (c) and (e), respectively, are the same.

November 26, 2001

By: Tanzina Chowdhury  
Gilberto M. Villacorta, Ph.D  
Registration No. 34,038

Tanzina S. Chowdhury  
Registration No. 46,624

KATTEN MUCHIN ZAVIS  
525 West Monroe Street  
Suite 1600  
Chicago, IL 60661-3693  
(312) 902-5200

*Applicants*

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
 For CRF Submission Help, call (703) 308-4212  
 PatentIn Software Program Support

Technical Assistance.....703-287-0200  
 To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**